No Result

View All Result

No products in the cart.

Home StudyGraphics

#VisualAbstract OAsIS: Ibrutinib, obinutuzumab, and venetoclax was well-tolerated and showed high response rates in both untreated and relapsed mantle cell lymphoma

byKathleen Lau

March 5, 2021

in StudyGraphics

#VisualAbstract: Relugolix combination therapy led to reduction in uterine fibroid symptoms

RelatedReports

Adalimumab aids in control of noninfectious uveitis

Chronic Disease

Younger age and systemic metastases may independently predict survival among patients with choroidal metastases

August 3, 2026

Variability in interpretation of breast biopsy slides associated with low verification of atypia and ductal carcinoma in situ

Chronic Disease

A digital mental health intervention may improve anxiety in breast cancer survivors

July 31, 2026

No significant increased risk of bladder cancer with pioglitazone use

Oncology

All-oral chemotherapy regimen tolerable and efficacious for newly diagnosed acute myeloid leukemia

July 23, 2026

Radiation plus hormone therapy may improve prostate cancer survival

Chronic Disease

Enzalutamide (Xtandi) and abiraterone (Zytiga) may have similar effectiveness in metastatic castration-sensitive prostate cancer

July 22, 2026

Many new pediatric asthma cases attributable to obesity

Food security status lower effectiveness of lifestyle-based weight loss approaches

Thrombophilia-associated stillbirth risk appears limited to factor V Leiden

2 Minute Medicine Rewind March 8, 2021

Relationships between depression and anxiety symptoms and adipocyte-derived proteins in postmenopausal women

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

No Result

View All Result

#VisualAbstract OAsIS: Ibrutinib, obinutuzumab, and venetoclax was well-tolerated and showed high response rates in both untreated and relapsed mantle cell lymphoma

RELATED REPORTS

#VisualAbstract: Relugolix combination therapy led to reduction in uterine fibroid symptoms

Food security status lower effectiveness of lifestyle-based weight loss approaches

RelatedReports

Recent Reports